Gyre Therapeutics Gains on China Drug Approval Pathway
Gyre Therapeutics (GYRE) stock jumps 14% after Chinese regulators agree to conditional approval pathway for Hydronidone, a first-in-class liver fibrosis treatment.
/ 1 item
#GYRE↓